Edition:
United States

Intercept Pharmaceuticals Inc (ICPT.OQ)

ICPT.OQ on NASDAQ Stock Exchange Global Select Market

103.21USD
4:00pm EDT
Change (% chg)

$1.01 (+0.99%)
Prev Close
$102.20
Open
$102.60
Day's High
$104.73
Day's Low
$102.00
Volume
149,578
Avg. Vol
236,256
52-wk High
$121.91
52-wk Low
$51.11

Chart for

About

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic... (more)

Overall

Beta: -1.78
Market Cap(Mil.): $3,302.94
Shares Outstanding(Mil.): 29.58
Dividend: --
Yield (%): --

Financials

  ICPT.OQ Industry Sector
P/E (TTM): -- 99.04 30.20
EPS (TTM): -13.11 -- --
ROI: -65.24 3.31 12.77
ROE: -215.41 2.31 14.92

BRIEF-Intercept Pharmaceuticals Says 2018 Worldwide Ocaliva Net Sales Currently Expected To Be Between $170 Mln-$185 Mln

* INTERCEPT PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS, ISSUES 2018 OCALIVA NET SALES GUIDANCE AND PROVIDES BUSINESS UPDATE

May 08 2018

BRIEF-Intercept Pharmaceuticals CEO Mark Pruzanski's FY 2017 Total Compensation Was $6.2 Million

* INTERCEPT PHARMACEUTICALS SAYS CEO MARK PRUZANSKI'S FY 2017 TOTAL COMPENSATION WAS $6.2 MILLION VERSUS $4.8 MILLION IN 2016 - SEC FILING Source text for Eikon: (http://bit.ly/2KlDqOX) Further company coverage:

Apr 27 2018

BRIEF-Intercept Pharmaceuticals Says Co's Board Increased Size Of Board From Nine Directors To Ten Directors

* INTERCEPT PHARMACEUTICALS SAYS EFFECTIVE APRIL 24, CO'S BOARD INCREASED SIZE OF BOARD FROM NINE DIRECTORS TO TEN DIRECTORS - SEC FILING Source text: [https://bit.ly/2JsU4uo] Further company coverage:

Apr 27 2018

BRIEF-Intercept Pharmaceuticals Announces Pricing Of Upsized $250 Mln Public Offering And Concurrent Private Placement Of Common Stock

* INTERCEPT PHARMACEUTICALS ANNOUNCES PRICING OF UPSIZED $250 MILLION PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT OF COMMON STOCK

Apr 05 2018

BRIEF-Intercept Sees Ocaliva Net Sales To Fall In Quarter Ended March 31

* EXPECTS NET SALES OF OCALIVA FOR QUARTER ENDED MARCH 31, TO BE SLIGHTLY LOWER THAN NET SALES OF OCALIVA FOR QUARTER ENDED DEC 31, 2017​ Source text (https://bit.ly/2uINGwG) Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Apr 04 2018

BRIEF-Intercept Pharma Says U.S. Court Granted Defendants Motion & Dismissed With Prejudice Derivative Lawsuit Purportedly Brought On Behalf Of Company

* INTERCEPT PHARMA - U.S. COURT GRANTED DEFENDANTS MOTION & DISMISSED WITH PREJUDICE DERIVATIVE LAWSUIT PURPORTEDLY BROUGHT ON BEHALF OF COMPANY

Mar 26 2018

BRIEF-Intercept Pharma Says Sumitomo Dainippon Pharma Enters Into Amendment To Certain License Agreement

* INTERCEPT PHARMA SAYS ON FEB 13, CO, SUMITOMO DAINIPPON PHARMA ENTERED INTO AMENDMENT TO CERTAIN LICENSE AGREEMENT DATED AS OF MARCH 29, 2011

Feb 16 2018

Competitors

Earnings vs. Estimates